Data from Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance Article Swipe
Simona Dalin
,
Mark R. Sullivan
,
Allison N. Lau
,
Beatrice Grauman-Boss
,
Helen S. Mueller
,
Emanuel Kreidl
,
Silvia Fenoglio
,
Alba Luengo
,
Jacqueline A. Lees
,
Matthew G. Vander Heiden
,
Douglas A. Lauffenburger
,
Michael T. Hemann
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/0008-5472.c.6511311.v1
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/0008-5472.c.6511311.v1
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer deaths in the United States. The deoxynucleoside analogue gemcitabine is among the most effective therapies to treat PDAC, however, nearly all patients treated with gemcitabine either fail to respond or rapidly develop resistance. One hallmark of PDAC is a striking accumulation of stromal tissue surrounding the tumor, and this accumulation of stroma can contribute to therapy resistance. To better understand how stroma limits response to therapy, we investigated cell-extrinsic mechanisms of resistance to gemcitabine. Conditioned media from pancreatic stellate cells (PSC), as well as from other fibroblasts, protected PDAC cells from gemcitabine toxicity. The protective effect of PSC-conditioned media was mediated by secretion of deoxycytidine, but not other deoxynucleosides, through equilibrative nucleoside transporters. Deoxycytidine inhibited the processing of gemcitabine in PDAC cells, thus reducing the effect of gemcitabine and other nucleoside analogues on cancer cells. These results suggest that reducing deoxycytidine production in PSCs may increase the efficacy of nucleoside analog therapies.Significance:This study provides important new insight into mechanisms that contribute to gemcitabine resistance in PDAC and suggests new avenues for improving gemcitabine efficacy.
Related Topics
Concepts
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.1158/0008-5472.c.6511311.v1
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4361824915
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4361824915Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/0008-5472.c.6511311.v1Digital Object Identifier
- Title
-
Data from Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine ResistanceWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-03-31Full publication date if available
- Authors
-
Simona Dalin, Mark R. Sullivan, Allison N. Lau, Beatrice Grauman-Boss, Helen S. Mueller, Emanuel Kreidl, Silvia Fenoglio, Alba Luengo, Jacqueline A. Lees, Matthew G. Vander Heiden, Douglas A. Lauffenburger, Michael T. HemannList of authors in order
- Landing page
-
https://doi.org/10.1158/0008-5472.c.6511311.v1Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1158/0008-5472.c.6511311.v1Direct OA link when available
- Concepts
-
Gemcitabine, Deoxycytidine, Pancreatic cancer, Cancer research, Nucleoside analogue, Nucleoside, Stromal cell, Hepatic stellate cell, Chemistry, Medicine, Pharmacology, Cancer, Internal medicine, BiochemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4361824915 |
|---|---|
| doi | https://doi.org/10.1158/0008-5472.c.6511311.v1 |
| ids.doi | https://doi.org/10.1158/0008-5472.c.6511311.v1 |
| ids.openalex | https://openalex.org/W4361824915 |
| fwci | |
| type | preprint |
| title | Data from Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10231 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9997000098228455 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | Pancreatic and Hepatic Oncology Research |
| topics[1].id | https://openalex.org/T10760 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9915000200271606 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2746 |
| topics[1].subfield.display_name | Surgery |
| topics[1].display_name | Pancreatitis Pathology and Treatment |
| topics[2].id | https://openalex.org/T10839 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9855999946594238 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2746 |
| topics[2].subfield.display_name | Surgery |
| topics[2].display_name | Pancreatic function and diabetes |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2780258809 |
| concepts[0].level | 3 |
| concepts[0].score | 0.9694111347198486 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q414143 |
| concepts[0].display_name | Gemcitabine |
| concepts[1].id | https://openalex.org/C2777844706 |
| concepts[1].level | 4 |
| concepts[1].score | 0.8044698238372803 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q422504 |
| concepts[1].display_name | Deoxycytidine |
| concepts[2].id | https://openalex.org/C2780210213 |
| concepts[2].level | 3 |
| concepts[2].score | 0.7019537687301636 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q212961 |
| concepts[2].display_name | Pancreatic cancer |
| concepts[3].id | https://openalex.org/C502942594 |
| concepts[3].level | 1 |
| concepts[3].score | 0.6332857608795166 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[3].display_name | Cancer research |
| concepts[4].id | https://openalex.org/C2777333352 |
| concepts[4].level | 3 |
| concepts[4].score | 0.601959228515625 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q2689559 |
| concepts[4].display_name | Nucleoside analogue |
| concepts[5].id | https://openalex.org/C2776543447 |
| concepts[5].level | 2 |
| concepts[5].score | 0.5622485280036926 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q28734 |
| concepts[5].display_name | Nucleoside |
| concepts[6].id | https://openalex.org/C16930146 |
| concepts[6].level | 2 |
| concepts[6].score | 0.5223209261894226 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q4381253 |
| concepts[6].display_name | Stromal cell |
| concepts[7].id | https://openalex.org/C176891718 |
| concepts[7].level | 2 |
| concepts[7].score | 0.514565646648407 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q1997459 |
| concepts[7].display_name | Hepatic stellate cell |
| concepts[8].id | https://openalex.org/C185592680 |
| concepts[8].level | 0 |
| concepts[8].score | 0.458187460899353 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[8].display_name | Chemistry |
| concepts[9].id | https://openalex.org/C71924100 |
| concepts[9].level | 0 |
| concepts[9].score | 0.34352582693099976 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[9].display_name | Medicine |
| concepts[10].id | https://openalex.org/C98274493 |
| concepts[10].level | 1 |
| concepts[10].score | 0.33019253611564636 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[10].display_name | Pharmacology |
| concepts[11].id | https://openalex.org/C121608353 |
| concepts[11].level | 2 |
| concepts[11].score | 0.3069227337837219 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[11].display_name | Cancer |
| concepts[12].id | https://openalex.org/C126322002 |
| concepts[12].level | 1 |
| concepts[12].score | 0.3015385866165161 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[12].display_name | Internal medicine |
| concepts[13].id | https://openalex.org/C55493867 |
| concepts[13].level | 1 |
| concepts[13].score | 0.14351347088813782 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[13].display_name | Biochemistry |
| keywords[0].id | https://openalex.org/keywords/gemcitabine |
| keywords[0].score | 0.9694111347198486 |
| keywords[0].display_name | Gemcitabine |
| keywords[1].id | https://openalex.org/keywords/deoxycytidine |
| keywords[1].score | 0.8044698238372803 |
| keywords[1].display_name | Deoxycytidine |
| keywords[2].id | https://openalex.org/keywords/pancreatic-cancer |
| keywords[2].score | 0.7019537687301636 |
| keywords[2].display_name | Pancreatic cancer |
| keywords[3].id | https://openalex.org/keywords/cancer-research |
| keywords[3].score | 0.6332857608795166 |
| keywords[3].display_name | Cancer research |
| keywords[4].id | https://openalex.org/keywords/nucleoside-analogue |
| keywords[4].score | 0.601959228515625 |
| keywords[4].display_name | Nucleoside analogue |
| keywords[5].id | https://openalex.org/keywords/nucleoside |
| keywords[5].score | 0.5622485280036926 |
| keywords[5].display_name | Nucleoside |
| keywords[6].id | https://openalex.org/keywords/stromal-cell |
| keywords[6].score | 0.5223209261894226 |
| keywords[6].display_name | Stromal cell |
| keywords[7].id | https://openalex.org/keywords/hepatic-stellate-cell |
| keywords[7].score | 0.514565646648407 |
| keywords[7].display_name | Hepatic stellate cell |
| keywords[8].id | https://openalex.org/keywords/chemistry |
| keywords[8].score | 0.458187460899353 |
| keywords[8].display_name | Chemistry |
| keywords[9].id | https://openalex.org/keywords/medicine |
| keywords[9].score | 0.34352582693099976 |
| keywords[9].display_name | Medicine |
| keywords[10].id | https://openalex.org/keywords/pharmacology |
| keywords[10].score | 0.33019253611564636 |
| keywords[10].display_name | Pharmacology |
| keywords[11].id | https://openalex.org/keywords/cancer |
| keywords[11].score | 0.3069227337837219 |
| keywords[11].display_name | Cancer |
| keywords[12].id | https://openalex.org/keywords/internal-medicine |
| keywords[12].score | 0.3015385866165161 |
| keywords[12].display_name | Internal medicine |
| keywords[13].id | https://openalex.org/keywords/biochemistry |
| keywords[13].score | 0.14351347088813782 |
| keywords[13].display_name | Biochemistry |
| language | en |
| locations[0].id | doi:10.1158/0008-5472.c.6511311.v1 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1158/0008-5472.c.6511311.v1 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5010257353 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Simona Dalin |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Simona Dalin |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5017691229 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Mark R. Sullivan |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Mark R. Sullivan |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5057349628 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-4250-7355 |
| authorships[2].author.display_name | Allison N. Lau |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Allison N. Lau |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5023385271 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Beatrice Grauman-Boss |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Beatrice Grauman-Boss |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5003463612 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-5813-873X |
| authorships[4].author.display_name | Helen S. Mueller |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Helen S. Mueller |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5023747385 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Emanuel Kreidl |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Emanuel Kreidl |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5083656191 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Silvia Fenoglio |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Silvia Fenoglio |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5004868995 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-4236-0229 |
| authorships[7].author.display_name | Alba Luengo |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Alba Luengo |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5085454999 |
| authorships[8].author.orcid | https://orcid.org/0000-0001-9451-2194 |
| authorships[8].author.display_name | Jacqueline A. Lees |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Jacqueline A. Lees |
| authorships[8].is_corresponding | False |
| authorships[9].author.id | https://openalex.org/A5006842434 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-6702-4192 |
| authorships[9].author.display_name | Matthew G. Vander Heiden |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Matthew G. Vander Heiden |
| authorships[9].is_corresponding | False |
| authorships[10].author.id | https://openalex.org/A5060106170 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-0050-989X |
| authorships[10].author.display_name | Douglas A. Lauffenburger |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Douglas A. Lauffenburger |
| authorships[10].is_corresponding | False |
| authorships[11].author.id | https://openalex.org/A5089833949 |
| authorships[11].author.orcid | https://orcid.org/0000-0001-6776-2163 |
| authorships[11].author.display_name | Michael T. Hemann |
| authorships[11].author_position | last |
| authorships[11].raw_author_name | Michael T. Hemann |
| authorships[11].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1158/0008-5472.c.6511311.v1 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Data from Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10231 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9997000098228455 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | Pancreatic and Hepatic Oncology Research |
| related_works | https://openalex.org/W2319201357, https://openalex.org/W4361836217, https://openalex.org/W3149052091, https://openalex.org/W2132958436, https://openalex.org/W2047788442, https://openalex.org/W2055810949, https://openalex.org/W2015735719, https://openalex.org/W2070851085, https://openalex.org/W4361824915, https://openalex.org/W2971848759 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1158/0008-5472.c.6511311.v1 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1158/0008-5472.c.6511311.v1 |
| primary_location.id | doi:10.1158/0008-5472.c.6511311.v1 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1158/0008-5472.c.6511311.v1 |
| publication_date | 2023-03-31 |
| publication_year | 2023 |
| referenced_works_count | 0 |
| abstract_inverted_index.a | 5, 48 |
| abstract_inverted_index.To | 67 |
| abstract_inverted_index.as | 91, 93 |
| abstract_inverted_index.by | 111 |
| abstract_inverted_index.in | 11, 129, 152, 174 |
| abstract_inverted_index.is | 4, 19, 47 |
| abstract_inverted_index.of | 8, 45, 51, 60, 80, 106, 113, 127, 136, 158 |
| abstract_inverted_index.on | 142 |
| abstract_inverted_index.or | 39 |
| abstract_inverted_index.to | 25, 37, 64, 74, 82, 171 |
| abstract_inverted_index.we | 76 |
| abstract_inverted_index.One | 43 |
| abstract_inverted_index.The | 15, 103 |
| abstract_inverted_index.all | 30 |
| abstract_inverted_index.and | 57, 138, 176 |
| abstract_inverted_index.but | 115 |
| abstract_inverted_index.can | 62 |
| abstract_inverted_index.for | 180 |
| abstract_inverted_index.how | 70 |
| abstract_inverted_index.may | 154 |
| abstract_inverted_index.new | 165, 178 |
| abstract_inverted_index.not | 116 |
| abstract_inverted_index.the | 12, 21, 55, 125, 134, 156 |
| abstract_inverted_index.was | 109 |
| abstract_inverted_index.PDAC | 46, 98, 130, 175 |
| abstract_inverted_index.PSCs | 153 |
| abstract_inverted_index.fail | 36 |
| abstract_inverted_index.from | 86, 94, 100 |
| abstract_inverted_index.into | 167 |
| abstract_inverted_index.most | 22 |
| abstract_inverted_index.that | 148, 169 |
| abstract_inverted_index.this | 58 |
| abstract_inverted_index.thus | 132 |
| abstract_inverted_index.well | 92 |
| abstract_inverted_index.with | 33 |
| abstract_inverted_index.PDAC, | 27 |
| abstract_inverted_index.These | 145 |
| abstract_inverted_index.among | 20 |
| abstract_inverted_index.cause | 7 |
| abstract_inverted_index.cells | 89, 99 |
| abstract_inverted_index.media | 85, 108 |
| abstract_inverted_index.other | 95, 117, 139 |
| abstract_inverted_index.study | 162 |
| abstract_inverted_index.treat | 26 |
| abstract_inverted_index.(PDAC) | 3 |
| abstract_inverted_index.(PSC), | 90 |
| abstract_inverted_index.United | 13 |
| abstract_inverted_index.analog | 160 |
| abstract_inverted_index.better | 68 |
| abstract_inverted_index.cancer | 9, 143 |
| abstract_inverted_index.cells, | 131 |
| abstract_inverted_index.cells. | 144 |
| abstract_inverted_index.deaths | 10 |
| abstract_inverted_index.ductal | 1 |
| abstract_inverted_index.effect | 105, 135 |
| abstract_inverted_index.either | 35 |
| abstract_inverted_index.limits | 72 |
| abstract_inverted_index.nearly | 29 |
| abstract_inverted_index.stroma | 61, 71 |
| abstract_inverted_index.tissue | 53 |
| abstract_inverted_index.tumor, | 56 |
| abstract_inverted_index.States. | 14 |
| abstract_inverted_index.avenues | 179 |
| abstract_inverted_index.develop | 41 |
| abstract_inverted_index.insight | 166 |
| abstract_inverted_index.leading | 6 |
| abstract_inverted_index.rapidly | 40 |
| abstract_inverted_index.respond | 38 |
| abstract_inverted_index.results | 146 |
| abstract_inverted_index.stromal | 52 |
| abstract_inverted_index.suggest | 147 |
| abstract_inverted_index.therapy | 65 |
| abstract_inverted_index.through | 119 |
| abstract_inverted_index.treated | 32 |
| abstract_inverted_index.analogue | 17 |
| abstract_inverted_index.efficacy | 157 |
| abstract_inverted_index.hallmark | 44 |
| abstract_inverted_index.however, | 28 |
| abstract_inverted_index.increase | 155 |
| abstract_inverted_index.mediated | 110 |
| abstract_inverted_index.patients | 31 |
| abstract_inverted_index.provides | 163 |
| abstract_inverted_index.reducing | 133, 149 |
| abstract_inverted_index.response | 73 |
| abstract_inverted_index.stellate | 88 |
| abstract_inverted_index.striking | 49 |
| abstract_inverted_index.suggests | 177 |
| abstract_inverted_index.therapy, | 75 |
| abstract_inverted_index.analogues | 141 |
| abstract_inverted_index.effective | 23 |
| abstract_inverted_index.important | 164 |
| abstract_inverted_index.improving | 181 |
| abstract_inverted_index.inhibited | 124 |
| abstract_inverted_index.protected | 97 |
| abstract_inverted_index.secretion | 112 |
| abstract_inverted_index.therapies | 24 |
| abstract_inverted_index.toxicity. | 102 |
| abstract_inverted_index.contribute | 63, 170 |
| abstract_inverted_index.mechanisms | 79, 168 |
| abstract_inverted_index.nucleoside | 121, 140, 159 |
| abstract_inverted_index.pancreatic | 87 |
| abstract_inverted_index.processing | 126 |
| abstract_inverted_index.production | 151 |
| abstract_inverted_index.protective | 104 |
| abstract_inverted_index.resistance | 81, 173 |
| abstract_inverted_index.understand | 69 |
| abstract_inverted_index.Conditioned | 84 |
| abstract_inverted_index.gemcitabine | 18, 34, 101, 128, 137, 172, 182 |
| abstract_inverted_index.resistance. | 42, 66 |
| abstract_inverted_index.surrounding | 54 |
| abstract_inverted_index.accumulation | 50, 59 |
| abstract_inverted_index.fibroblasts, | 96 |
| abstract_inverted_index.gemcitabine. | 83 |
| abstract_inverted_index.investigated | 77 |
| abstract_inverted_index.Deoxycytidine | 123 |
| abstract_inverted_index.deoxycytidine | 150 |
| abstract_inverted_index.equilibrative | 120 |
| abstract_inverted_index.transporters. | 122 |
| abstract_inverted_index.adenocarcinoma | 2 |
| abstract_inverted_index.cell-extrinsic | 78 |
| abstract_inverted_index.deoxycytidine, | 114 |
| abstract_inverted_index.PSC-conditioned | 107 |
| abstract_inverted_index.deoxynucleoside | 16 |
| abstract_inverted_index.deoxynucleosides, | 118 |
| abstract_inverted_index.efficacy.</p></div> | 183 |
| abstract_inverted_index.<div>Abstract<p>Pancreatic | 0 |
| abstract_inverted_index.therapies.</p>Significance:<p>This | 161 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 12 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8500000238418579 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.08368865 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |